Venous endothelin receptor function in patients with chronic heart failure.

Cardiac preload reduction through venodilatation is beneficial in chronic heart failure. The recent development of endothelin receptor antagonists for possible therapeutic use in heart failure has hastened the need for a clearer understanding of the venoconstrictor actions of endothelin-1 in this disease. Two main subtypes of endothelin receptor, ET(A) and ET(B), exist in human blood vessels. We studied the venoconstrictor effects of endothelin-1 (a non-selective ET(A) and ET(B) agonist) and sarafotoxin S6c (a selective ET(B) agonist) in vivo in patients with chronic heart failure and in age-matched healthy controls. On separate days at least 1 week apart, locally active doses of endothelin-1 or sarafotoxin S6c were infused into a suitable dorsal hand vein for 1 h, and the venous internal diameter was measured using a displacement technique. Venoconstriction in response to endothelin-1 was significantly blunted in heart failure patients compared with controls (26+/-7% and 51+/-6% peak reduction in vein calibre respectively; P=0.013). Venoconstriction to sarafotoxin S6c was similar in heart failure patients and controls (17+/-5% and 17+/-4% peak reduction in vein calibre respectively). Both ET(A) and ET(B) receptors mediate venoconstriction in healthy subjects and in patients with chronic heart failure. Optimal inhibition of the venoconstrictor effects of endothelin-1 in chronic heart failure may therefore require administration of an antagonist with ET(A)- and ET(B)-receptor-blocking properties. Chronic heart failure may be associated with a selective decrease in venous ET(A) receptor sensitivity, but further studies are required to clarify the functional significance of this observation.

[1]  Y. Sugishita,et al.  Down-regulation of ET(B) receptor, but not ET(A) receptor, in congestive lung secondary to heart failure. Are marked increases in circulating endothelin-1 partly attributable to decreases in lung ET(B) receptor-mediated clearance of endothelin-1? , 1997, Life sciences.

[2]  D. Webb,et al.  Endothelium-dependent modulation of responses to endothelin-I in human veins. , 1993, Clinical science.

[3]  B. Löffler,et al.  Role of endothelin in the maintenance of blood pressure in conscious rats with chronic heart failure. Acute effects of the endothelin receptor antagonist Ro 47-0203 (bosentan). , 1994, Circulation.

[4]  R. Nutt,et al.  Identification of high affinity endothelin-1 receptor subtypes in human tissues. , 1991, Biochemical and biophysical research communications.

[5]  M. J. Sumner,et al.  Endothelin ETA and ETB receptors mediate vascular smooth muscle contraction , 1992, British journal of pharmacology.

[6]  S. Nakanishi,et al.  Cloning and expression of a cDNA encoding an endothelin receptor , 1990, Nature.

[7]  D. Webb,et al.  Direct and sympathetically mediated venoconstriction in essential hypertension. Enhanced responses to endothelin-1. , 1994, The Journal of clinical investigation.

[8]  J. McMurray,et al.  Fortnightly Review: Diagnosis and management of heart failure , 1994, BMJ.

[9]  A. Davenport,et al.  Human endothelin receptors characterized using reverse transcriptase-polymerase chain reaction, in situ hybridization, and subtype-selective ligands BQ123 and BQ3020: evidence for expression of ETB receptors in human vascular smooth muscle. , 1993, Journal of cardiovascular pharmacology.

[10]  R. Rodeheffer,et al.  Increased plasma concentrations of endothelin in congestive heart failure in humans. , 1992, Mayo Clinic proceedings.

[11]  J. Rouleau,et al.  Coordinated upregulation of the cardiac endothelin system in a rat model of heart failure. , 1998, Journal of cardiovascular pharmacology.

[12]  A. Lerman,et al.  Enhanced Coronary Vasoconstriction to Endothelin-BReceptor Activation in Experimental Congestive Heart Failure , 1996 .

[13]  A. Lerman,et al.  Enhanced coronary vasoconstriction to endothelin-B-receptor activation in experimental congestive heart failure. , 1996, Circulation.

[14]  Y. Sugishita,et al.  IS078 Expression of endothelin (ET)-1, ET_A, receptor, ET_B receptor, ET-converting enzyme and cellular distribution of ET-1 staining in the failing heart due to myocardial infarction in rats , 1998 .

[15]  P. Vallance,et al.  Endothelin receptors mediating functional responses in human small arteries and veins , 1994, British journal of pharmacology.

[16]  F. Tristani,et al.  Effect of Vasodilator Therapy on Mortality in Chronic Congestive Heart Failure. Results of a Veterans Administration Cooperative Study , 1987 .

[17]  W. H. Aellig.  Clinical pharmacology, physiology and pathophysiology of superficial veins--2. , 1994, British journal of clinical pharmacology.

[18]  K. Margulies,et al.  Endothelin in experimental congestive heart failure in the anesthetized dog. , 1990, The American journal of physiology.

[19]  J. McMurray,et al.  Plasma Endothelin in Chronic Heart Failure , 1992, Circulation.

[20]  M. Böhm,et al.  Expression of endothelin-1, endothelin-converting enzyme, and endothelin receptors in chronic heart failure. , 1999, Circulation.

[21]  Y. Sugishita,et al.  Inhibition of myocardial endothelin pathway improves long-term survival in heart failure , 1996, Nature.

[22]  J. Vane,et al.  Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[23]  P. Binkley,et al.  Plasma Endothelin Correlates With the Extent of Pulmonary Hypertension in Patients With Chronic Congestive Heart Failure , 1992, Circulation.

[24]  D. Webb,et al.  Vasodilator effects of endothelin-converting enzyme inhibition and endothelin ETA receptor blockade in chronic heart failure patients treated with ACE inhibitors. , 1996, Circulation.

[25]  S. Goldman,et al.  Importance of Venodilatation in Prevention of Left Ventricular Dilatation After Chronic Large Myocardial Infarction in Rats: A Comparison of Captopril and Hydralazine , 1989, Circulation research.

[26]  T. Katsuya,et al.  AT1 and AT2 angiotensin receptor gene expression in human heart failure. , 1997, Circulation.

[27]  D. Webb,et al.  Endothelin ETA and ETB receptors cause vasoconstriction of human resistance and capacitance vessels in vivo. , 1995, Circulation.

[28]  W. Waldhäusl,et al.  Effect of endothelin-1 in man. , 1990, Circulation.

[29]  W. H. Aellig.  Clinical pharmacology, physiology and pathophysiology of superficial veins--1. , 1994, British journal of clinical pharmacology.

[30]  W. H. Aellig.  A new technique for recording compliance of human hand veins. , 1981, British journal of clinical pharmacology.

[31]  P. Vanhoutte,et al.  Endothelins 1 and 3 and big endothelin-1 contract isolated human placental veins. , 1993, Journal of cardiovascular pharmacology.

[32]  A. Lerman,et al.  Endothelin Has Biological Actions at Pathophysiological Concentrations , 1991, Circulation.

[33]  MichaelBöhm,et al.  Expression of Endothelin-1, Endothelin-Converting Enzyme, and Endothelin Receptors in Chronic Heart Failure , 1999 .

[34]  D. Webb,et al.  The pharmacology of human blood vessels in vivo. , 1995, Journal of vascular research.

[35]  P. Hunziker,et al.  Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure , 1995, The Lancet.

[36]  P. Binkley,et al.  Alpha-adrenergic component of the sympathetic nervous system in congestive heart failure. , 1990, Circulation.

[37]  Y. Sugishita,et al.  Expression of endothelin-1, ETA and ETB receptors, and ECE and distribution of endothelin-1 in failing rat heart. , 1999, The American journal of physiology.

[38]  P. Vallance,et al.  Human saphenous vein contains both endothelin ETA and ETB contractile receptors. , 1994, European journal of pharmacology.

[39]  T. Sakurai,et al.  Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor , 1990, Nature.